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Abstract : 
We reported a case of a 51-year-old woman with acute respiratory failure for whom ventricular septum 
defect combined with right-left shunt was successfully performed with the use of high-flow nasal cannula 
oxygenation (HFNCO) therapy. She had suffered from ventricular septum defect (VSD) and pulmonary 
artery banding was performed at four-year old. However, residual VSD had not been pointed out. Until 
today, she had been able to work and do housework. When she suffered from pneumonia and admitted to the 
hospital, she also pointed out chronic cardiac failure combined with pulmonary hypertension (pulmonary 
arterial pressure 115/45(76) mmHg, pulmonary vascular resistance 874 dyne/sec/cm5). Thereafter, home 
oxygen therapy (HOT) was started (2 L/min O2). This time, she suffered from pneumonia and hypoxemia 
under HOT (SpO2 84 %). She complained of dyspnea even at rest and had labored breathing through pursed 
lips after a short conversation, defined as class IV in the Hugh-Jones classification. She was transferred to 
our intensive care unit (ICU) and underwent HFNCO (Flow rate 60 L/min, FiO2 0.6). After starting HFNCO, 
respiratory rate was decreased from 35 to 25 times/min and dyspnea was improved immediately. Day 5, she 
transferred to regular ward. Day 7, HFNCO was stopped and conventional oxygen therapy was started. The 
patient was transferred back to the local hospital for rehabilitation on Day 15.
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Introduction
We reported the case of a patient with acute 
respiratory failure for whom ventricular septum 
defect combined with right-left  shunt was 
successfully performed with the use of high-flow 
nasal cannula oxygenation (HFNCO) therapy and 
avoided tracheal intubation.
Case Presentation (Figure)
51 year-old female. 161 cm in height, 41.3 
kg in weight. Immediately after birth, cardiac 
murmur was pointed out. She had suffered from 
ventricular septum defect (VSD) and pulmonary 
artery banding was performed at four-year old. 
After surgery, her growth and development were 
normal. Until today, despite of feeling shortness 
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in breathing and palpitation in the everyday life, 
she had been able to work and do housework. 
She suffered from pneumonia and admitted to 
the hospital at forty-eight years old. She also 
pointed out chronic cardiac failure due to residual 
VSD combined with pulmonary hypertension 
(pulmonary arterial pressure 115/45(76) mmHg, 
pulmonary vascular resistance 874 dyne/sec/cm5) 
and thereafter home oxygen therapy (HOT) was 
started (2 L/min of oxygen). Right–left shunt blood 
flow through residual VSD was also pointed out. 
Medication (sildenafil citrate 60mg, Ambrisentan 
5mg) was started. After medication, pulmonary 
hypertension was not improved (PA 105/49(68) 
mmHg, PVR 539 dyne/sec/cm5). Continuous 
infusion of prostacyclin (27.9 ng/kg/min) was also 
started. After prostacyclin infusion, pulmonary 
hypertension was improved (PA 80/34(55) mmHg, 
PVR 417 dyne/sec/cm5). Oxygenation was kept 
at SpO2 90% under 4L/min of oxygen with nasal 
oxygen cannula. Cardiothoracic rate (CTR) was 
gradually increased to 65 % without apparent 
dyspnea. Afterward, she registered the lung 
transplantation recipient. VSD closure was planned 
at the lung transplantation surgery. This time, she 
suffered from pneumonia and hypoxemia under 
HOT (SpO2 90%). She complained of dyspnea even 
at rest and had labored breathing through pursed 
lips after a short conversation, 
defined as class IV in the Hugh-
Jones classification. She was 
transferred to our intensive care 
unit (ICU). At admission to the 
ICU, heart rate (HR) was 130 
beats/min, non-invasive blood 
pressure (NIBP) was 110/60 
mmHg, respiratory rate (RR) was 
35 times/min, SpO2 was 84 % 
under 10 L/min of oxygen with 
oxygen mask. Consciousness 
was clear. To prevent increasing 
r ight- le ft  shunt  b lood f low 
through residual VSD, positive 
pressure ventilation via tracheal 
intubation was not plan to done. However, she 
refused non-invasive positive pressure ventilation 
(NIPPV) by discomfort of a tight mask and a forced 
air flow. Therefore, HFNCO (Flow rate 60 L/min, 
FiO2 0.6) was started. Immediately after starting 
HFNCO, RR was decreased to from 35 to 25 times/
min. Dyspnea and Oxygenation was improved 
(Before: PH 7.427, PO2 45.8 mmHg, PCO2 49 mmHg; 
After: PH 7.424, PO2 75.4 mmHg, PCO2 49.7 mmHg). 
Haemophilus influenza was detected in sputum 
culture. As antimicrobial treatment, meropenem 
1.5 g/day and minocycline 200 mg/day were done. 
Afterward, respiratory failure was gradually 
improved and discharged from ICU to the ward on 
Day 5. HFNCO was kept for 7days after admission 
and changed to 2 L/min of oxygen by nasal cannula. 
Day 15, she discharged to other hospital for 
respiratory rehabilitation. 
Discussion
This is a success case for treating cardiac failure 
using HFNCO, because of refusing NPPV therapy 
by patient. In this case, positive pressure ventilation 
via tracheal intubation might induce a right cardiac 
failure by increasing pulmonary artery pressure, 
because of a right-left shunt combined with residual 
VSD. Therefore, another oxygen therapy was 
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needed. In recent years, NPPV has been done in 
routine clinical therapy for patients suffering from 
left cardiac failure.1 However, asynchronies for the 
spontaneous breathing is a serious problem leading 
for discontinuing NPPV therapy.2 Asynchronies 
for spontaneous breathing might magnitude the 
changes of intrathoracic pressure and induce an 
increasing pulmonary artery pressure. Therefore, 
asynchronies for spontaneous breathing must be 
prevented to treat a cardiac failure, especially in a 
cardiac shunt disease. From asynchronies points 
of view, HFNCO might be suitable for patients 
with cardiac shunt diseases, because HFNCO is 
not a forced positive pressure ventilation device. 
However, there has not been an obvious evidence 
for improving cardiac failure.2
HFNCO has been reported to provide four 
superior effects for improving oxygenation 
compared with traditional oxygen therapy via face-
mask.3-8 First is to maintain stable inspiratory 
oxygen concentration. Second is to increase 
tidal volume by PEEP effect induced by high 
flow gases. Third is to decreasing end-tidal CO2 
by decreasing rebreathing and washout effect. 
Fourth is to increasing residual lung capacity 
induced by increasing intrathoracic pressure. 
HFNCO provided another effect to decreasing 
dyspnea by humidifying and warming nasal mucosa 
using humidified and warmed inspired gases.9, 
10 In addition, HFNCO could prevent excessive 
airway pressure because it consisted of the open 
respiratory circuit and non-sedated patients 
could avoided it consciously. These effects were 
contributed for improving respiratory muscle 
fatigue in patients with acute respiratory failure 
leading to decrease systemic oxygen consumption. 
 However, HFNCO system could not provide a 
respiratory monitoring system such as airway 
pressure,  a ir  f low and respiratory rate .  A 
prospective observational study to study impact 
of HFNCO therapy on intensive care unit patients 
reported HFNCO could decrease respiratory 
rate more certainly than conventional oxygen 
therapy via face-mask.11 Another report in patients 
underwent critical care also indicated the effects of 
decreasing respiratory rate.12 Respiratory rate must 
be one of important index for evaluating the effect 
of HFNCO. In this care, after starting HFNCO, 
oxygenation could not be increased but the feeling 
of discomfort and respiratory rate were improved 
rapidly. Therefore, respiratory effort might be 
decreased judged from this effects. Further study 
should be done to reveal the indicator of HFNCO 
effects under clinical setting.
Conclusion
Under careful respiratory rate monitoring, 
HFNCO might be a useful device for patients with 
acute respiratory failure combined with a residual 
right-left shunt cardiac disease who is difficult to 
do positive pressure ventilation.
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